July 11 (Reuters) - Kelly Partners Group Holdings Ltd (KPG) :
- FY24 PRELIM GROUP REVENUE OF A$105M-A$110M
- PRELIM FY24 OPERATING BUSINESS EBITDA MARGIN OF 30-31%
- SHARE BUY BACK PROGRAM IS IN PLACE UNTIL 30 AUGUST AND WILL BE RENEWED FOR FURTHER 12 MONTHS
- Forums
- ASX - By Stock
- KPG
- News: KPG Kelly Partners Says FY24 Prelim Group Revenue Of A$105M-A$110M
News: KPG Kelly Partners Says FY24 Prelim Group Revenue Of A$105M-A$110M
Featured News
Add KPG (ASX) to my watchlist
|
|||||
Last
$7.60 |
Change
-0.020(0.26%) |
Mkt cap ! $342M |
Open | High | Low | Value | Volume |
$7.96 | $7.96 | $7.60 | $90.81K | 11.70K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | $7.59 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$7.66 | 37444 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | 7.590 |
3 | 4067 | 7.500 |
1 | 3000 | 7.460 |
2 | 527 | 7.450 |
1 | 400 | 7.410 |
Price($) | Vol. | No. |
---|---|---|
7.660 | 37444 | 1 |
7.990 | 1800 | 1 |
8.000 | 2471 | 7 |
8.100 | 143 | 1 |
8.300 | 3449 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
KPG (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online